We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 10,720,000 ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

"Acadia submits MAA to EMA for Rett syndrome therapy" was originally created and published by Pharmaceutical Technology, a ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) and keeping the price ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a decline, ending the day at $16.9 which represents a decrease of $-1.00 or -5.59% from the prior close of $17.9. The stock opened at $18.15 and touched a ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

Fintel reports that on January 3, 2025, Guggenheim downgraded their outlook for ACADIA Pharmaceuticals (NasdaqGS:ACAD) from ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...

Big things are happening at Acadia Pharmaceuticals (NASDAQ:ACAD), and investors should take note. Fresh off a blockbuster update at the J.P. Morgan Healthcare Conference, Acadia revealed it's ...

Diversified Trust Co boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 9.8% during the fourth ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency ...